The Synthesis and Chemistry of Certain Anthelmintic Benzimidazoles LB

Total Page:16

File Type:pdf, Size:1020Kb

The Synthesis and Chemistry of Certain Anthelmintic Benzimidazoles LB Parasitology Today, vol. 6, no. 4. I990 107 The Synthesis and Chemistry of Certain Anthelmintic Benzimidazoles LB. Townsend and D.S. Wise A basis for interest in the benzimidazole ring system as a nucleus Benzimidazole, as the name implies, is a bicyclic ring system in from which to develop potential chemotherapeutic agents was which benzene has been fused to the 4- and 5-position of the established in the I95Os when it was found that 5,6-dimethyl- I - heterocycle (imidazole; Box I). Benzimidazole compounds in (a-D-ribofiranosyljbenzimidazole (I) was an integral part ofthe general, and benzimidazole carbamates in particular, are crys- talline materials, with fairly high melting points and are relatively insoluble in water. Compounds that are unsubstituted on either of the imidazole nitrogen atoms possess both acidic and basic characteristics. Modifications of the benzimidazole ring system that have been made during the search for anthelmintic activity are summarized in Box 2. Combinations of the modifications at positions 2- and 5- of the molecule has provided the most active drugs. The synthetic pathways to the various benzimi- structure of vitamin 6,~ As a result of these interests and dazoles usually proceeds through two steps, first the construc- extensive studies, one health related arena that has benefited tion of a benzene ring containing the desired substituents and a greatly has been the treatment ofparasitic diseases. The discovery I ,2-diamine grouping, followed by the ring closure of the of thiabendazole in I96 I further spurred chemists around the I ,2-diaminobenzene (o-phenylenediamine) derivative to con- world to design and synthesize several thousand benzimidazoles struct the imidazole ring. In many cases, this ring closure is the for screening for anthelmirltic activity but less than twenty ofthem have reached commercial use. Much ofthis work has been done RE 1;; - by pharmaceutical companies and is only reported in the patent 3: 2 3r literature. In this paper, Leroy Townsend and Dean Wise review d’ ’ FR the development ofsome cfthe synthetic methods that have been o - phenylenediamine critical to the preparation of the benzimidazoles ofanthelmintic R, R’ = ring substitution importance. On/y a few ,nolecules that demonstrate the pro- final step in the synthesis of the desired benzimidazole. How- cesses are discussed here, but numerous reviews of the synthesis ever, in other instances this ring closure is followed by exten- andchemistry ofother benzimidazoles are available’“. sive derivatization of the ring system or of the existing exocyclic substituents (Box 3). Box I. Tautomerism and isomerism The discovery4 in I96 I that 2-(4’-thiazolyl)benzimidazole The systematic numbering of the benzimidazole ring system is (thiabendazole) possessed a very potent broad spectrum of shown in structure 1. Although benzimidazole is depicted in I as activity against gastrointestinal parasites was the breakthrough pssessing the proton at N,, there actually exists a rapid that opened up a new era in the treatment of parasitic diseases. Exchange between the -NlH- and =N- nitrogen atoms, and two In the initial studies, a group of researchers at Merck prepared tautomers, I and II, may be drawn for the benzimidazole mol- thiabendazole by a condensation of o-phenylenediamine with thiazole-4-carboxamide in the presence of the dehydrating I < , $pW agent, polyphosphoric acid. This reaction was found to be quite ; I 9 a - a 7 H’ (acldlc) I II aNMJ ecule. Tautomerism occurs through either an intermolecular H” process involving two or more benzimidazole molecules or Thiabendazole through interactions witlh a protic solvent such as water. It renders the 5- and 6- positions, and any group at that position in general in nature and several hundred derivatives, including the the ring system, chemically equivalent. In N-substituted benzimi- 2-(2’-furyl)-,2-phenyl-,2-(2’-naphthyl)-, and 2-(S’-thiazoyl)- dazoles, tautomerism is no longer possible and two distinct congeners, were also prepared to determine the best candi- non-equivalent molecules or isomers may be isolated and charac- date for commercial development. Both the 2-phenyl- deriva- terized. For example, the two dimethylated benzimidazoles tive and thiabendazole were very active drugs, and were shown are an isomeric pair of non-equivalent molecules, while the mono-methylated molecules are tautomers and equivalent. QNH*+,,u aniline 2 @ 1990. Elsewr Science Publlshers Ltd. (LlK)OI 6947071901802.00 108 Parasitology Today, vol. 6, no. 4, I990 Box 2. Chemical Structures of Some Benzimidazole Anthelmintics Benzimidazoles Benzimidazole Carbamates NHCO&H, R = H Thiabendazole R = 1 \ i _ Mebendazole” crystals, mp 304°C crystals, acetic acid, mp 288°C insoluble in water, slightly soluble in alcohol insoluble in water o- - R = (CH,),CHOCONH- Cambendazole i _ FIubendazole’” crystals, mp 238°C crystals, mp 280°C insoluble in water, soluble in alcohol insoluble in water Prodrugs 0 Ciclobendazole” R= t- , NHCO,Me crystals, mp 250°C ’ 1 N=C<NHCWe e&$;lmp ,29”c Albendazole” R I CH3CHfiHaS- a\ NHCOCH,OCH, crystals, mp 208°C R = CHsCH$H20 - ;;i$ia;;t;&C practically insoluble in water Netobimin crystals, water soluble ; NHC-NHCO,Me Thiophanate (methyl) ‘I crystals, soluble in alcohol a\ NHCNHCO,Me k! Parbendazoleg crystals, R = CH,CH&H,CH,- mp 225°C. insoluble in water studied further. A new, efficient procedure for the conversion Since hydroxylation was occurring at the 5-position, analogs of N-arylamidines with hypochlorite and a base to form of thiabendazole with different groups at this position were benzimidazoles was devised by the Merck group5, and this developed. As a potential candidate, 5-aminothiabendazole (9) discovery made it economically practical to market the was prepared by a condensation of 4-nitrophenylenediamine 2-phenyl derivative and thiabendazole. In this procedure it is (7) with (2) to furnish 5-nitrothiabendazole (8). The nitro unnecessary to prepare the o-phenylenediamine compound group of compound (8) was then reduced to furnish 5- because aniline is used as a starting material. Thus, to prepare aminothiabendazole (9). Compound (9) was nearly (80%) as thiabendazole (4) aniline is reacted with 4-cyanothiazole (2) in active as the parent thiabendazole. Acylation of the 5-amino the presence of aluminium trichloride (a Lewis acid), to give the intermediate N-arylamidine hydrochloride (3). The critical NH, oxidative cyclization to give (4) is then carried out by treating + (3) with sodium hypochlorite in the presence of a base. The NH, latter reaction has been accomplished commercially in one step, but it may also be performed stepwise through the intermediate (5). 7 ltwas later found that both thiabendazoleand 2-phenylbenz A8* imidazole suffer from an enzymatic hydroxylation at the S-position to give (a), which inactivates the drug and therefore i!zzzFHOW;menzymatic 9 H ~~‘:‘, thiabendazole 6 limits its effectiveness. To overcome this problem, investi- gators began to prepare second generation benzimidazoles H with structural modifications that might prevent metabolic IO cambendazole inactivation. These studies led to an abundance of potential functional portion of (9) with isopropyl chloroformate pro- anthelmintic benzimidazoles, and many methods of prep- duced the 5-isoproxycarbonylamino derivative (I 0), which aration. was marketed under the name cambendazole’. Later, Parasitology Today, vol. 6, no 4, I990 109 effective. Several compounds were prepared that possessed thisgroupatthe2-position.Oneofthesecompounds,prepared by the reaction of 4-but+o-phenylenediamine (I 3) with car- bomethoxycyanamide (14) in boiling propanol, was methyl 5-butyl-2-benzimidazolylcarbamate (I 5; parbendazole). thiabendazole Following the introduction of this compound, additional IO II drugs were produced by several pharmaceutical companies. cambendazole was prepared directly from thiabendazole by Janssen Pharmaceutics produced mebendazole, flubendazole, an electrophilic substitution of a nitrene or nitrene-like and ciclobendazole” among others; Smith Kline and French intermediate derived from isopropyl azidoformate, initiated discovered al bendazole ’ ’ , oxibendazole ’ 2, and fenbenda- by heat or UV light7. Another unique synthesis of cambenda- zole13; and Syntex developed oxfendazole’4. To prepare zole involves a reduction of the 3-(4-thiazolyl)benzotriazine these benzimidazoles, several new ring closing reagents were I -oxide ( I I)‘. Through a systematic study involving a modification of the thiazole ring at the 2-position of thiabendazole, workers at Smith Kline and French found that the thiocarbonate com- pound (I 2a) possessed anthelmintic activity’. This led to the H preparation of 2-acylarninobenzimidazoles (I Zb), 2-benz- I3 I4 15 parbendazole ’ ONpNH!,, = employed or invented and these 2-methoxycarbamate .N a H synthons are shown in Table I. To prepare mebendazole, flubendazole, ciclobendazole, 12a IL = S,R E CC&Is 12b :Y=O,R=akyl and a variety of benzimidazoles containing a group attached to 12~ .K=O,R-akoxy the 5-position of the benzimidazole by a carbonyl (C=O) 124 :K=O,R=akylan-im linkage, a general reaction scheme was developed by re- imidazolylcarbamates (I I!c)and 2-benzimidazolylureas (I 2d). searchers at Janssen (see Box 3). In this synthetic sequence, the All of these compounds ‘possessed anthelmintic activity, how- initial step is to append to ring A, the group which becomes the ever, the 2-methylcarbamate derivative stood out as the most 5-carbonyl linked substituent. This
Recommended publications
  • United States Patent (19) 11 Patent Number: 5,861,142 Schick (45) Date of Patent: *Jan
    USOO586 1142A United States Patent (19) 11 Patent Number: 5,861,142 Schick (45) Date of Patent: *Jan. 19, 1999 54 METHOD FOR PROMOTING HAIR, NAIL, 0 090 368 10/1983 European Pat. Off.. AND SKIN KERATINIZATION 0 187 012 7/1986 European Pat. Off.. 0 224 249 6/1987 European Pat. Off.. 76 Inventor: Mary Pichler Schick, 2027 Old Forge b 5. g i. As E. Way, Marietta, Ga. 30068 0 0 W.e "9CO * Notice: This patent issued on a continued pros- 95/16447 6/1995 WIPO. ecution application filed under 37 CFR OTHER PUBLICATIONS 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. Biochemistry Pharm., The interaction of benzimidazole Cat 154(a)(2). bamates with mammalian microtobule protein Vol. 28, p. 268O-2682. Davidse and Flach, “Differential Binding of Methyl 21 Appl. No.: 621,473 Benzimidazol-2-yl Carbamate to Fungal iustin S y 22 Filed: Mar. 25, 1996 Mechanism of Resistance to this Antimitotic Agent in 6 Mutant Strains of Aspergillus Nidulans”, Journal of Cell 51 Int. Cl. ....................................................... A61K 7/06 Biology, vol. 72, 1977, pp. 174-193. 52 U.S. Cl. ............................ 424/61; 424/701; 424/451; Fisher, et. al., “Efficacy of fenbenzalole and piperazine 424/464; 424/484; 424/489; 514/365; 514/395; against developing Stages of toxocara and toxascaris in 514/937; 514/944 dogs”, The Veterinary Record, vol. 132, No. 19, May 8, 58 Field of Search ..................................... 424/401, 701, 1943, pp. 473–475. 424/451, 464, 484, 489; 514/365, 395, 937, 944 (List continued on next page.) Primary Examiner Jvothsna Venkat 56) References Cited AOC, Agent, Or E".
    [Show full text]
  • Chemotherapy of Gastrointestinal Helminths
    Chemotherapy of Gastrointestinal Helminths Contributors J. H. Arundel • J. H. Boersema • C. F. A. Bruyning • J. H. Cross A. Davis • A. De Muynck • P. G. Janssens • W. S. Kammerer IF. Michel • M.H. Mirck • M.D. Rickard F. Rochette M. M. H. Sewell • H. Vanden Bossche Editors H. Vanden Bossche • D.Thienpont • P.G. Janssens UNIVERSITATS- BlfiUOTHElC Springer-Verlag Berlin Heidelberg New York Tokyo Contents CHAPTER 1 Introduction. A. DAVIS A. Pathogenic Mechanisms in Man 1 B. Modes of Transmission 2 C. Clinical Sequelae of Infection 3 D. Epidemiological Considerations 3 E. Chemotherapy 4 F. Conclusion 5 References 5 CHAPTER 2 Epidemiology of Gastrointestinal Helminths in Human Populations C. F. A. BRUYNING A. Introduction 7 B. Epidemiological or "Mathematical" Models and Control 8 C. Nematodes 11 I. Angiostrongylus costaricensis 11 II. Anisakis marina 12 III. Ascaris lumbricoides 14 IV. Capillaria philippinensis 21 V. Enterobius vermicularis 23 VI. Gnathostoma spinigerum 25 VII. Hookworms: Ancylostoma duodenale and Necator americanus . 26 VIII. Oesophagostoma spp 32 IX. Strongyloides stercoralis 33 X. Ternidens deminutus 34 XI. Trichinella spiralis 35 XII. Trichostrongylus spp 38 XIII. Trichuris trichiura 39 D. Trematodes 41 I. Echinostoma spp 41 II. Fasciolopsis buski 42 III. Gastrodiscoides hominis 44 IV. Heterophyes heterophyes 44 V. Metagonimus yokogawai 46 X Contents E. Cestodes 47 I. Diphyllobothrium latum 47 II. Dipylidium caninum 50 III. Hymenolepis diminuta 51 IV. Hymenolepis nana 52 V. Taenia saginata 54 VI. Taenia solium 57 VII. Cysticercosis cellulosae 58 References 60 CHAPTER 3 Epidemiology and Control of Gastrointestinal Helminths in Domestic Animals J. F. MICHEL. With 20 Figures A. Introduction 67 I.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Comparative Genomics of the Major Parasitic Worms
    Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • C.8. C.9. /S.II G Courses Prof
    Cursuri Romeo T. Cristina T. Romeo Cursuri C.8. C.9. Image soure: ®® http://www.colonlove.com/assets/images/Parasites.jpg /S.II Antiparasitic medication Courses Prof. Romeo T. Cristina® Introduction thethetheantiparasitic therapy isisis based ononon aaa large number ofofof substances, thethethe majority ofofof them areareare syntheticsynthetic.... Most antiparasitic drugs affect thethethe neuromuscular system ofofof thethethe parasite bybyby blocking thethethe neuromuscular junctions, with thethethefinal result ofofof: of ::: paralysis, death and disposaldisposal.... itititisisis known that helminths have also aaa reversible paralysis, sososothat ififif they areareare not eliminated ininin due time, they will recoverrecover. ... Courses Prof. Romeo T. Cristina® The substances ofofof tehthe tehorganophosphorus group eraare era knownforfor fortheir effectiveness onon onboth helminths and ectoparasitesaerare aergrafted ininin their useuse usebybyby relative high toxicity ... Their mechanism isisis based onon on blocking ehtthe eht acetylcholinesterase enzyme, which isisis tehthe tehenzyme necessaryforfor the forthe thehydrolysis ofofof acetylcholineacetylcholine. ... ByBy Byblocking this enzyme, tehthe tehmediator can onno onlongerbebe be releasedreleased,teh,,, the tehstimulus remains open resulting htethe hte exhaustion and death theofofof the theparasiteparasite. ... Courses Prof. Romeo T. Cristina® Other substances interfere with thethethe processes ofofofATP phosphorylationphosphorylation.... dichlorophenol, niclosamide, benzimidazoles
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,872,013 Leunissen Et Al
    USOO5872O13A United States Patent (19) 11 Patent Number: 5,872,013 Leunissen et al. (45) Date of Patent: *Feb. 16, 1999 54 UNIVERSALLY APPLICABLE DETECTION 56) References Cited SYSTEM BASED ON ULTRA SMALL COLLOIDAL METAL PARTICLES U.S. PATENT DOCUMENTS 4,206,094 6/1980 Yen et al.. 75 Inventors: Johannes Leonardus Maria 4,313,734 2/1982 Leuvering. Leunissen, Merksplas; Marc Joris De 4.420,558 12/1983 De Mey et al.. Brabander, Zoersel, both of Belgium; 4,446,238 5/1984 De Mey et al. ........................ 436/527 Petrus Franciscus Elisabeth Maria 4,752,567 6/1988 DeBrabander et al. 436/525 X 4,775,636 10/1988 Moeremans et al. ................... 436/518 Van de Plas, Breda, Netherlands 4,877,647 10/1989 Klabunde ................................ 427/123 73 Assignee: Janssen Pharmaceutica N.V., Beerse, 5,120,643 6/1992 Ching et al. ........................... 435/7.92 Belgium FOREIGN PATENT DOCUMENTS * Notice: This patent issued on a continued pros 158 746 10/1985 European Pat. Off.. ecution application filed under 37 CFR 165 643 12/1985 European Pat. Off.. 1.53(d), and is subject to the twenty year 167834 1/1986 European Pat. Off.. patent term provisions of 35 U.S.C. 154(a)(2). OTHER PUBLICATIONS Horisberger, “Colloidal Gold as a tool in molecular biol 21 Appl. No.: 539,131 ogy”, TIBS, Nov., 1983 pp. 395-397. Roth, “The Colloidal Gold Marker System for Light and 22 Filed: Oct. 4, 1995 Electron Microscopic Cytochemistry,” in Immunocytochem Related U.S. Application Data istry 2, Academic Press, London, (1984), pp. 217-284.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]